Fulgent Genetics, Inc. (NASDAQ:FLGT) Receives $27.00 Average PT from Analysts

Fulgent Genetics, Inc. (NASDAQ:FLGT) has received an average rating of “Hold” from the five research firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $27.00.

Several brokerages have recently commented on FLGT. Piper Sandler restated a “neutral” rating and issued a $15.00 target price (down from $30.00) on shares of Fulgent Genetics in a research note on Tuesday, May 5th. Zacks Research downgraded Fulgent Genetics from a “strong-buy” rating to a “hold” rating in a research note on Monday, February 9th. Finally, Wall Street Zen downgraded Fulgent Genetics from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 9th.

Institutional Trading of Fulgent Genetics

Several large investors have recently made changes to their positions in FLGT. Farther Finance Advisors LLC grew its stake in shares of Fulgent Genetics by 69.3% in the 4th quarter. Farther Finance Advisors LLC now owns 1,339 shares of the company’s stock valued at $35,000 after buying an additional 548 shares during the period. Kestra Advisory Services LLC bought a new position in Fulgent Genetics in the 4th quarter valued at about $35,000. Caitong International Asset Management Co. Ltd lifted its position in Fulgent Genetics by 214.6% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,834 shares of the company’s stock valued at $48,000 after acquiring an additional 1,251 shares in the last quarter. Raymond James Financial Inc. bought a new position in Fulgent Genetics in the 2nd quarter valued at about $49,000. Finally, Flagship Harbor Advisors LLC bought a new position in Fulgent Genetics in the 4th quarter valued at about $56,000. 48.06% of the stock is currently owned by institutional investors and hedge funds.

Fulgent Genetics Price Performance

Shares of FLGT opened at $17.11 on Monday. The stock has a 50-day moving average of $15.82 and a 200-day moving average of $22.11. The company has a market cap of $509.02 million, a PE ratio of -7.16 and a beta of 0.88. Fulgent Genetics has a one year low of $13.46 and a one year high of $31.04.

Fulgent Genetics (NASDAQ:FLGT) last issued its earnings results on Friday, February 27th. The company reported $0.16 EPS for the quarter, beating the consensus estimate of $0.02 by $0.14. The company had revenue of $83.34 million during the quarter, compared to the consensus estimate of $85.38 million. Fulgent Genetics had a negative return on equity of 3.24% and a negative net margin of 23.04%.Fulgent Genetics has set its FY 2026 guidance at -1.450–1.450 EPS. Analysts expect that Fulgent Genetics will post -2.81 EPS for the current fiscal year.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.

Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.